Search results
Showing 496 to 510 of 1300 results for heart OR cardi* OR arrythmia
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS52Show all sections
Sections for QS52
- Quality statements
- Quality statement 1: Identification and assessment of peripheral arterial disease
- Quality statement 2: Comorbidity assessment
- Quality statement 3: Supervised exercise programmes
- Quality statement 4: Imaging
- Quality statement 5: Angioplasty for intermittent claudication
- About this quality standard
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Evidence-based recommendations on vamorolone (Agamree) for treating Duchenne muscular dystrophy in people 4 years and over.
Show all sections
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Transmyocardial laser revascularisation for refractory angina pectoris (IPG301)
Evidence-based recommendations on transmyocardial laser revascularisation for refractory angina pectoris. This involves open heart surgery to drill holes on the heart muscle using a laser beam.
View recommendations for IPG301Show all sections
Sections for IPG301
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
or conservative management in heart valve disease. Source guidance details Comes from guidance Heart valve disease...
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
in people with repaired or replaced heart valves. Source guidance details Comes from guidance Heart valve disease...
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making